OBJECTIVE: To identify the characteristics associated with glycemic response to newly initiated insulin therapy. RESEARCH DESIGN AND METHODS: We identified 1,139 type 2 diabetic patients who initiated insulin therapy between 1 January 2009 and 30 June 2010. Outcomes of interest were the proportion of patients achieving A1C <7% and mean change in A1C within 3-9 months. RESULTS: Mean A1C at insulin initiation was 8.2 vs. 9.2% among those who did and did not attain A1C <7% (P < 0.001). Within a mean of 5 months, 464 (40.7%) patients attained A1C <7%. In multivariable analyses controlling for insulin regimen, dose, and oral agent use, preinsulin A1C was responsible for nearly all the explained variance in A1C change. Each one percentage point of preinsulin A1C reduced the probability of attaining <7% by 26% (odds ratio 0.74 [95% CI 0.68-0.80]). CONCLUSIONS: Insulin initiation at lower levels of A1C improves goal attainment and independently increases glycemic response.
OBJECTIVE: To identify the characteristics associated with glycemic response to newly initiated insulin therapy. RESEARCH DESIGN AND METHODS: We identified 1,139 type 2 diabeticpatients who initiated insulin therapy between 1 January 2009 and 30 June 2010. Outcomes of interest were the proportion of patients achieving A1C <7% and mean change in A1C within 3-9 months. RESULTS: Mean A1C at insulin initiation was 8.2 vs. 9.2% among those who did and did not attain A1C <7% (P < 0.001). Within a mean of 5 months, 464 (40.7%) patients attained A1C <7%. In multivariable analyses controlling for insulin regimen, dose, and oral agent use, preinsulin A1C was responsible for nearly all the explained variance in A1C change. Each one percentage point of preinsulin A1C reduced the probability of attaining <7% by 26% (odds ratio 0.74 [95% CI 0.68-0.80]). CONCLUSIONS:Insulin initiation at lower levels of A1C improves goal attainment and independently increases glycemic response.
Authors: Andreas Liebl; Stephen Jones; Marian Benroubi; Conxa Castell; Albert Goday; Marie Aline Charles; Helen T Smith; Claudia Nicolay; Alexander Simpson Journal: Curr Med Res Opin Date: 2011-02-22 Impact factor: 2.580
Authors: Andrew J Karter; Howard H Moffet; Jennifer Liu; Melissa M Parker; Ameena T Ahmed; Alan S Go; Joe V Selby Journal: Am J Manag Care Date: 2007-11 Impact factor: 2.229
Authors: Rury R Holman; Kerensa I Thorne; Andrew J Farmer; Melanie J Davies; Joanne F Keenan; Sanjoy Paul; Jonathan C Levy Journal: N Engl J Med Date: 2007-09-21 Impact factor: 91.245
Authors: Gregory A Nichols; Shravanthi R Gandra; Chiun-Fang Chiou; Mary S Anthony; Maria Alexander-Bridges; Jonathan B Brown Journal: Curr Med Res Opin Date: 2010-01 Impact factor: 2.580
Authors: Haoda Fu; Dachuang Cao; Kristina S Boye; Bradley Curtis; Dara L Schuster; David M Kendall; Haya Ascher-Svanum Journal: Diabetes Ther Date: 2015-07-05 Impact factor: 2.945
Authors: Erin S LeBlanc; A Gabriela Rosales; Sumesh Kachroo; Jayanti Mukherjee; Kristine L Funk; Jennifer L Schneider; Gregory A Nichols Journal: BMJ Open Diabetes Res Care Date: 2015-02-24